Chemo for stomach cancer that has spread to the abdomen lining
Part of Cancer, Digestive system clinical trials.
This trial tests giving chemotherapy into the abdomen during surgery for stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis). It aims to see if this approach can help control the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that has spread to the lining of your abdomen (peritoneum).
- You are 18 or older.
- You are able to do daily activities with some help (ECOG 0-2), and if you have trouble, it's because of the cancer, not other health issues.
- After 4-6 months of standard chemotherapy, your cancer hasn't spread outside the abdomen (except for small metastases in liver, ovaries, or lungs that can be removed or treated).
- You have adequate kidney, liver, and blood cell function as shown by routine lab tests.
- You can understand and sign an informed consent form in English.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial looks at a way to give chemotherapy into the abdomen (through a small tube during laparoscopy) for certain stomach cancers. It aims to see whether this approach improves cancer control and surgical outcomes for people whose tumors can potentially be removed.
This study tests whether a thorough surgery to remove stomach cancer in the abdomen, followed by chemotherapy given through the belly and by vein, can improve outcomes. It’s for people newly diagnosed with stomach cancer that has limited spread to the belly lining.
This trial tests a special type of chemotherapy that is heated and delivered directly into the belly during surgery (called HIPEC). It uses two drugs, cisplatin and paclitaxel, and is for people with stomach cancer who are at high risk of the cancer returning in the lining of the belly.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
Hear when a new Synchronous Gastric Peritoneal Carcinomatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.